top of page
추상적인 검은 파도
GR-topbg copy.jpg
recombinant Botulinum Toxin concept image

Recombinant Botulinum Toxin

Setting a new benchmark for next-generation toxin therapies through recombinant BoNT engineering

Targeted mRNA Delivery

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

The Next Frontier in Biotech

MVRIX is a biotechnology company focused on advancing new possibilities beyond the limits of conventional medicines.

main_bg01.png

The Next


Frontier


in Biotech

MVRIX는 첨단 바이오 기술을 통해 기존 의약품의 한계를 뛰어넘어 새로운 가능성을 열어가는 혁신적인 연구를 수행하는 기업입니다

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We go beyond existing limits

to provide better choices

through Innovative R&D

3

Platform Technology

80

Patents

20 +

Collaborative partners

bg_maintech_exp.jpg

Our Technology

Smarter Innovation

We lead the future of therapeutics with three protein-engineering platforms.

Science 01
Navibody Platform

A targeted mRNA delivery platform that enhances antibody–LNP specificity and improves production efficiency.

  • In vivo CAR-T

  • Navibody Service

Science 02
rBoNT Platform

A recombinant botulinum toxin platform based on engineered recombinant production, enabling faster and safer development.

  • Faster, Longer rBoNT(Cosmetics)

Science 03
Virucidal Platform

A virucidal platform based on validated rHDL production technology, designed to address enveloped viruses such as COVID-19, influenza, and mpox.

  • Anti-COVID-19

Latest News

MVRIX in motion

We capture and share the moments of change we are creating.

2/26/26
한경바이오인사이트포럼 2026에서 In Vivo CAR-T 차세대 리더십 제시
11/5/25
Bio-Europe 2025 참가
6/11/25
Attended Plaque award ceremony(2025 Super-Gap Startup 1000+ DIPS Project)
5/20/25
MVRIX signs MBT-002 licensing deal with Eyegene

Our Partners

Growing Synergy

MVRIX grows through strategic partnerships and collaboration.

Press Release

Reaching Further

Discover the latest updates from MVRIX.

default
엠브릭스, 유전자 치료제용 전달 플랫폼 美 특허 등록

12/16/25

한국경제

default
[초격차 스타트업] 엠브릭스 대표 정상원 "앞으로 4년 후 IPO 추진, 신약 개발이 목표"

6/27/25

Business post

default
[인터뷰] ‘스타트업 1000+’ 지원사업 선정된 엠브릭스 정상원 대표

6/25/25

Kyeongin Ilbo

default
KIT '바이오헬스 신약·소재 분야 초격차기업' 선정

4/16/25

Kukinews

bottom of page